13 Nutrients That Scientifically Improve Sleep Quality and Circadian Health

Sleep deprivation is a modern epidemic linked to increased all-cause mortality and elevated risk of cardiovascular disease, obesity, type 2 diabetes, cancer, and neurodegeneration. Despite these consequences, most adults chronically fail to achieve the recommended 7–9 hours of restful sleep per night. Behavioral interventions like sleep hygiene and light management help, but dietary protocols targeting specific nutraceuticals offer an additional, underutilized lever.

This narrative review, conducted via systematic MEDLINE and Cochrane searches using the PICO framework, evaluated 13 compounds for their effects on sleep quantity, quality, onset latency, efficiency, and next-day alertness. Evidence was drawn primarily from randomized controlled trials, systematic reviews, and meta-analyses, with emphasis on human studies across diverse clinical populations.

Melatonin (2–3 mg, 1–2 hours before bed) demonstrated robust evidence for reducing sleep onset latency and improving total sleep time, particularly in children with neurodevelopmental disorders, adults with delayed sleep phase disorder, and older individuals with declining endogenous melatonin synthesis. Magnesium (500 mg–1 g nightly) improved subjective and objective sleep measures, likely via GABA receptor modulation and cortisol suppression. Omega-3 fatty acids (1–2 g/day of combined DHA and EPA) supported melatonin biosynthesis and reduced nighttime awakenings. Tart cherry juice and kiwifruit showed promising results in small trials, with kiwifruit consumption (2 fruits, 1 hour pre-bed) associated with significant improvements in sleep onset and efficiency. Apigenin, delivered via chamomile extract (400 mg twice daily), demonstrated anxiolytic and sedative effects through GABA-A receptor binding, with benefits for postpartum sleep and generalized anxiety. Valerian root (200 mg nightly) showed moderate evidence for reducing sleep latency. L-theanine (200–400 mg/day) promoted relaxation without sedation by increasing alpha brain wave activity and reducing cortisol. Glycine (3 g, 1 hour pre-bed) improved subjective sleep quality and reduced daytime fatigue in sleep-restricted individuals by lowering core body temperature. Ashwagandha (600–700 mg/day for 4–8 weeks) reduced sleep onset latency and anxiety-driven insomnia. Myoinositol (2000 mg pre-bed) showed preliminary benefits for anxiety-related sleep disturbance. Rhodiola rosea and phosphatidylserine had insufficient evidence to recommend specific dosing but showed cortisol-modulating and neuroprotective potential relevant to stress-induced sleep disruption.

The review identifies several vulnerable populations—including older adults, shift workers, jet lag sufferers, and patients with traumatic brain injury, dementia, or psychiatric illness—for whom these compounds may be especially beneficial. A practical reference table is provided summarizing recommended intakes, timing, forms, and dietary sources for each compound.

Caveats include small sample sizes across many trials, heterogeneous methodologies, reliance on self-reported outcomes, and limited long-term safety data. The authors note that severe sleep disorders require medical supervision and pharmacological intervention, and that nutraceuticals should be viewed as adjuncts, not replacements, for foundational sleep hygiene.